within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX26_Vortioxetine;

model Vortioxetine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.75,
    Cl = 9.166666666666666e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 2.6,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0021666666666666666,
    Tlag = 10.200000000000001,
    Vdp = 1.3,
    k12 = 2.3611111111111114e-05,
    k21 = 2.3611111111111114e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Vortioxetine</td></tr><tr><td>ATC code:</td><td>N06AX26</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2600</td><td>L</td></tr>
    <tr><td>clearance:</td><td>33</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Vortioxetine is an antidepressant approved for the treatment of major depressive disorder (MDD) in adults. It acts as a serotonin modulator and stimulator, functioning as a serotonin reuptake inhibitor and agonist or antagonist at various serotonin receptors. It is currently approved and in use for the treatment of depression in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in healthy adult volunteers after single and multiple oral doses of vortioxetine.</p><h4>References</h4><ol><li><p>Chen, G, et al., &amp; Nomikos, G (2018). Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. <i>Clinical pharmacokinetics</i> 57(6) 673–686. DOI:<a href=\"https://doi.org/10.1007/s40262-017-0612-7\">10.1007/s40262-017-0612-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29189941/\">https://pubmed.ncbi.nlm.nih.gov/29189941</a></p></li><li><p>Areberg, J, et al., &amp; Naik, H (2014). Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 115(6) 552–559. DOI:<a href=\"https://doi.org/10.1111/bcpt.12256\">10.1111/bcpt.12256</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24766668/\">https://pubmed.ncbi.nlm.nih.gov/24766668</a></p></li><li><p>Naik, H, et al., &amp; Areberg, J (2016). A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 118(5) 344–355. DOI:<a href=\"https://doi.org/10.1111/bcpt.12513\">10.1111/bcpt.12513</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26525043/\">https://pubmed.ncbi.nlm.nih.gov/26525043</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AX26 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Vortioxetine;
